

Opportunity Title: FDA Postdoctoral Glyco-technology Lab Fellowship

Opportunity Reference Code: FDA-CDER-2024-1412

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CDER-2024-1412

How to Apply Connect with ORISE...on the GO! Download the new ORISE GO mobile app in the Apple App

<u>Store</u> or <u>Google Play Store</u> to help you stay engaged, connected, and informed during your ORISE experience and beyond!

A complete application consists of:

- An application
- Transcripts Click here for detailed information about acceptable transcripts
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to <a href="https://oran.org">ORISE.FDA.CDER@oran.org</a>. Please include the reference code for this opportunity in your email.

Application Deadline 9/30/2024 3:00:00 PM Eastern Time Zone

Description \*Applications will be reviewed on a rolling-basis.

**FDA Office and Location:** A research opportunity is available within the Food and Drug Administration (FDA) in The Center for Drug Evaluation and Research (CDER), The Office of Pharmaceutical Quality Research (OPQR), Office of Pharmaceutical Quality (OPQ), located at Silver Spring, Maryland.

The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This work covers more than just medicines.

**Research Project:** This project will research the glycan release from glycoprotein drugs with chemo-enzymatic methods and characterize glycan structures with state-of-the-art technologies, including H(U)PLC and mass spectrometry (MS).

**Learning Objectives:** Under the guidance of the mentor, the participant will learn state-of-the-art technologies and develop novel technologies for feasible analysis of glycosylation of therapeutic glycoprotein drugs, including monoclonal antibody (mAb) drugs, fusion proteins, enzyme-replacement therapies, plasma products, etc. in manufacturing control and characterization.

**Appointment Length:** The appointment will initially be for one year but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

Level of Participation: The appointment is full time.

**Citizenship Requirements:** This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-



OAK RIDGE INSTITUTE

Generated: 8/22/2024 1:38:03 AM



Opportunity Title: FDA Postdoctoral Glyco-technology Lab Fellowship

Opportunity Reference Code: FDA-CDER-2024-1412

U.S. citizen applicants should refer to the **Guidelines for Non-U.S. Citizens** Details page of the program website for information about the valid immigration statuses that are acceptable for program participation.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

## **FDA Ethics Requirements**

If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see FDA Ethics for Nonemployee Scientists.

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- · The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

Qualifications The qualified candidate should have received a doctoral degree in one of the relevant fields, or be currently pursuing a doctoral degree with completion before September 29, 2024. Degree must have been received within five years of the appointment start date.

Preferred Skills:

· Skills in mass spectrometry and in glyco-chemistry and/or proteomics.

Generated: 8/22/2024 1:38:03 AM



Opportunity Title: FDA Postdoctoral Glyco-technology Lab Fellowship

Opportunity Reference Code: FDA-CDER-2024-1412

## Eligibility Requirements

- Degree: Doctoral Degree received within the last 60 months or anticipated to be received by 9/30/2024 12:00:00 AM.
- Discipline(s):
  - Chemistry and Materials Sciences (4\_●)
  - Life Health and Medical Sciences (<u>7</u>.

Affirmation I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.) I have read the FDA Ethics Requirements.

Generated: 8/22/2024 1:38:03 AM